Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 3
ClinicalTrials.gov
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
INTERVENTIONAL
Inicio: 1 de ene de 2017
ID: NCT03121586
Terminado
Fase 3
ClinicalTrials.gov
An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
INTERVENTIONAL
Inicio: 25 de may de 2018
ID: NCT03567291
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
INTERVENTIONAL
Inicio: 25 de abr de 2016
ID: NCT02603432
Completado
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 9 de jul de 2015
ID: NCT02446899
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
INTERVENTIONAL
Inicio: 1 de jun de 2016
ID: NCT02767804
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
INTERVENTIONAL
Inicio: 5 de abr de 2017
ID: NCT02972840
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
INTERVENTIONAL
Inicio: 11 de abr de 2014
ID: NCT01892345
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
INTERVENTIONAL
Inicio: 8 de dic de 2015
ID: NCT02571777
Terminado
Fase 2
ClinicalTrials.gov
A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer
INTERVENTIONAL
Inicio: 1 de feb de 2007
ID: NCT00372996
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events
INTERVENTIONAL
Inicio: 1 de jun de 2012
ID: NCT01609582
Completado
Fase 4
ClinicalTrials.gov
A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
INTERVENTIONAL
Inicio: 1 de nov de 2011
ID: NCT01456936
Terminado
ClinicalTrials.gov
A Prospective Natural History Study of Progression of Physical Impairment, Activity Limitation and Quality of Life in Duchenne Muscular Dystrophy.
OBSERVATIONAL
Inicio: 1 de sept de 2012
ID: NCT01753804
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
INTERVENTIONAL
Inicio: 30 de nov de 2017
ID: NCT03312634
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
INTERVENTIONAL
Inicio: 9 de abr de 2015
ID: NCT02312258
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
INTERVENTIONAL
Inicio: 28 de dic de 2018
ID: NCT03650114
Completado
Fase 2
ClinicalTrials.gov
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01590459
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease
INTERVENTIONAL
Inicio: 17 de oct de 2014
ID: NCT02251275
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
INTERVENTIONAL
Inicio: 1 de may de 2014
ID: NCT02160145
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Doses of CFZ533 in Patients With Moderately Active Proliferative Lupus Nephritis
INTERVENTIONAL
Inicio: 12 de sept de 2018
ID: NCT03610516
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).
INTERVENTIONAL
Inicio: 14 de jul de 2022
ID: NCT05126277
Anterior
1
...
4
5
6
...
434
Siguiente
Filtros